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environment suggested by the presence of synovial hyper-
vascularization.Figure 1. Prolidase protein expression: A) Hipertrophy synovial of patient
with OA B) Normal synovium710
MANUAL LABOR OCCUPATIONS INCREASE THE SHORT-TERM
INCIDENCE OF KNEE OSTEOARTHRITIS IN JAPANESE, BUT NOT
CAUCASIAN SUBJECTS
K.M. Leyland y, M.T. Sanchez-Santos y, S. Muraki z, A. Judge y,
T.D. Spector x, D.J. Hart x, J. Newton y, C. Cooper k,y, N. Yoshimura z,
N.K. Arden y,k. yUniv. of Oxford, Oxford, United Kingdom; zUniv. of Tokyo,
Tokyo, Japan; x St. Thomas’ Hosp., London, United Kingdom; kUniv. of
Southampton, Southampton, United Kingdom
Purpose: To determine the interacting role of occupation and obesity
on the risk of incident knee osteoarthritis (OA) among Caucasian and
Japanese women.
Methods: We used data from women in two prospective community-
based cohorts, the UK based Chingford study and the Japanese Research
on Osteoarthritis/osteoporosis Against Disability (ROAD) study. Incident
radiographic knee osteoarthritis (RKOA) was deﬁned as having Kellgren
and Lawrence (K/L) grade 0 or 1 in both knees at baseline and a K/L
grade 2 or greater at follow up. Follow-up x-rays were taken after a
median of 4 years after baseline for Chingford and 3 years in ROAD. The
cut-off for a normal BMI was 25 kg/m2 for the Caucasian subjects and
23 kg/m2 for the Japanese subjects. Occupation was divided into
manual versus non-manual (i.e. sedentary/moderate activity) for both
populations based on self-assessment.
Multivariable logistic regression models assessed of risk of obesity,
occupation and their interaction on incident RKOA, controlling for age,
hand grip strength, walking distance, smoking and alcohol intake.
Results: 12.4% of Caucasian and 14.5% of Japanese women developed
incident RKOA in at least one knee. Being overweight/obese was asso-
ciated with an increased risk of incident RKOA in both populations
(Caucasian OR 1.7 [95% CI 1.0, 2.8]; Japanese OR 2.5 [95% CI 1.3, 4.9]),
however having a manual labour occupation was only signiﬁcantly
associated with incident RKOA in the Japanese subjects (OR 2.8 [95% CI
1.3, 5.8]). No signiﬁcant interaction between BMI category and occu-
pation was found for either population (Chingford p¼0.070; ROAD
p¼0.291), however the Japanese population showed a slight increase in
risk for manual labour occupations in the overweight/obese categoryTable 1
Proﬁle of Participants by presence or absence of back pain
All (n¼22) L
Age (years) 65.64 (8.43) 6
BMI (kg/m2) 29.08 (5.63) 2
Number of Co- morbidities 0.95 (0.89) 0
Hip symptom Duration (months) 31.27 (35.12) 3
Back symptom Duration (months) 89.31 (110.15) 8
Hip Pain severity (VAS) (0-10cm) 4.87 (2.8) 4
Back Pain severity (VAS) (0-10cm) 3.99 (3.94) 5
WOMAC Function (0-68) 32.27 (15.71) 3
RMDQ (0-24) 7.32 (6.56) 1(OR 4.7 [95%CI 1.4, 16.1]) compared to the normal group (OR 2.6 [95% CI
1.0, 6.7]). No signiﬁcant association was found in the Caucasian women
for either BMI category (normal: OR 0.7 [95%CI 0.2, 2.1]; overweight/
obese: OR 2.0 [95%CI 0.9, 4.8]).
Conclusions: Manual labour occupations increase the short-term risk
of incident RKOA in Japanese, but not Caucasian women. This risk was
greater for overweight/obese subjects than those in the normal weight
category.
711
THE PREVALENCE AND CLINICAL SIGNS AND SYMPTOMS OF LOW
BACK PAIN IN PEOPLE WITH HIP OSTEOARTHRITIS: A CROSS
SECTIONAL STUDY
H.P. French y, B. O’Donnell y, P. O’Connell z, V. Cuddy z. yRoyal Coll. of
Surgeons in Ireland, Dublin, Irelzand; zBeaumont Hosp., Dublin, Ireland
Purpose: Low Back Pain (LBP) has been widely reported in the hip OA
population and commonly coined as Hip-Spine syndrome. Estimates of
prevalence are variable and range between 21.2-61.5%. To date, most
studies investigating LBP prevalence in hip OA have been conducted in
those with advanced disease awaiting replacement surgery. The aim of
this study was to ﬁrstly determine the prevalence LBP in people with
hip OA attending outpatient clinics in an acute hospital setting. The
second aim was to identify the clinical features associated with LBP in
people with hip OA based on self-report symptoms and physical
examination.
Methods: A cross-sectional observational study involving a one-off
assessment was undertaken. Local ethics committee approval was
obtained. Back and hip pain severity were measured using the Visual
Analogue Scale (VAS). The Western Ontario and McMaster universities
osteoarthritis index (WOMAC) and the Roland Morris Disability Ques-
tionnaire (RMDQ) were used to measure hip and back-related disability
respectively. Physical assessment consisted of lumbar spinal palpation,
pelvic pain provocation tests and active hip and spinal Range of Motion
(ROM). Reproduction of the participant’s usual symptoms was recorded
for all procedures. Variables were analysed based on presence or
absence of back pain, using non-parametric Mann-Whitney U tests for
continuous variables.
Results: A total of 22 people with radiographically conﬁrmed hip OA
were recruited (13 female). Total prevalence of LBP was 16/22
(72.7%). The most common pain location for both LBP (n¼16) and
non-LBP groups (n¼6) was the groin, lateral thigh, knee and anterior
thigh, with no signiﬁcant difference in the number of pain locations
between groups (p¼0.13). There was a signiﬁcant moderate corre-
lation between hip and LBP severity (r¼0.58, p¼0.005), duration of
hip and LBP symptoms (r¼0.61, p¼0.02), but not between hip
severity and duration of symptoms (r¼0.07, p¼0.73). Those with LBP
were signiﬁcantly younger and had higher WOMAC pain and dis-
ability (Table 1). Mean hip symptom duration of LBP group was over
twice that of non-LBP group, but did not reach statistical signiﬁcance
(p¼0.08). In relation to ROM, only hip ﬂexion was signiﬁcantly dif-
ferent between the two groups (LBP mean¼ 73.91; non-LBP
ean¼91.33; p¼0.03). The median number of painful spinal levels was
higher in LBP group, but not signiﬁcant (LBP median¼5, IRQ¼7.75;
non LBP median¼1, IRQ¼7.5; p¼013). Median number of positive
pain provocation tests was also higher in LBP group (median¼1,
range¼4; non-LBP median¼1, range¼1; p¼0.03).
Conclusions: A high LBP prevalence rate was reported in a cohort
of people with hip OA in an acute hospital setting. Those with LBPBP group (n¼16) Non LBP group (n¼6) p-value
2.44 (7.19) 74.17 (4.83) 0.001
8.97 (6.28) 28.40 (3.87) 0.59
.81 (0.92) 1.33 (0.82) 0.20
7.19 (37.8) 15.50 (22) 0.08
9.31 (110.51) 0 N/A
.98 (2.86) 4.57 (2.87) 0.87
.48 (3.61) 0 N/A
7.81 (12.31) 17.50 (14.90) 0.01
0.06 (5.56) 0 N/A
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S399were younger and had higher levels of hip-related pain and
disability. The LBP group also had a higher number of painful
spinal levels and pelvic pain provocation tests. Results should be
interpreted with caution due to the low sample size. Further
research is warranted to explore the cause and effect relationship
and underlying pain mechanisms associated with co-existing hip
OA and LBP.DSPCC 35 mg TID (n[ 98) DSPCC 35 mg BID (n[ 104) Placebo (n[ 103)
(n[ 96) (n[ 102) (n[ 96)
Subjects with  30% reduction from baseline to week 12 75 (78.1 %) 70 (68.6%) 58 (60.4%)
P value 0.0078 0.2271
Subjects with  50% reduction from baseline to week 12 60 (62.5%) 57 (55.9%) 44 (45.8%)
P value 0.0205 0.1575
P-values are compared with placebo.712
LOWER-DOSE DICLOFENAC CAPSULES DEVELOPED USING
SOLUMATRIX FINE PARTICLE TECHNOLOGY RESULT IN CLINICALLY
MEANINGFUL IMPROVEMENTS IN PAIN IN A PHASE 3 STUDY OF
PATIENTS WITH OSTEOARTHRITIS
C. Young y, D. Parenti y, M. Hochberg z. y Iroko Pharmaceuticals, LLC,
Philadelphia, PA, USA; zUniv. of Maryland, Baltimore, MD, USA
Purpose: Osteoarthritis (OA) is characterized by acute and chronic pain
and reduced physical function. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) are frequently prescribed for the management of OA pain. As a
class, NSAIDs are associated with dose-related serious gastrointestinal,
cardiovascular, and renal adverse events which has prompted interna-
tional health authorities and the United States Food and Drug Admin-
istration to recommend that NSAIDs be used at the lowest effective dose
for the shortest possible duration. Diclofenac submicron particle con-
taining capsules (DSPCC) consisting of submicron drug particles and a
proprietary combination of excipients were developed using SoluMa-
trix Fine Particle Technology to provide efﬁcacy at lower doses than
commercially available diclofenac drug products and are licensed for
treatment of mild-to-moderate acute pain in adults. As previously
reported, DSPCC 35 mg three times daily (TID) signiﬁcantly reduced the
Western Ontario and McMaster University Osteoarthritis Index
(WOMAC) pain subscale score compared with placebo (P ¼ 0.0024) in a
phase 3 study in adults with OA pain of the hip or knee. Therewas some
evidence of improvement in theWOMAC pain subscale score compared
with placebo for DSPCC 35 mg twice daily (BID), although this did not
achieve statistical signiﬁcance (P ¼ 0.08). We report the results for
measures of clinically meaningful pain relief following treatment with
low-dose DSPCC in the phase 3 study.
Methods: This multicenter, randomized, double-blind, placebo-con-
trolled study enrolled patients 40 years with clinically and radio-
logically conﬁrmed (Kellgren-Lawrence grade II-III) hip or knee OA pain.
Eligible patients were chronic NSAID and/or acetaminophen users with
baseline WOMAC pain subscale scores 40 mm (based on 100-mm
Visual Analog Scale) and a documented OA ﬂare (15-mm increase in
WOMAC pain subscale score from screening). Patients were random-
ized to receive DSPCC 35 mg TID, DSPCC 35 mg BID, or placebo for 12
weeks. Efﬁcacy parameters included responder rates for patients who
achieved a reduction of 10 mm in pain intensity from baseline based
on theWOMAC pain subscale score at week 2, 6, and 12; the proportion
of patients with a reduction (0%-100%) in WOMAC pain subscale score
at week 12 (continuous responder analysis); and the proportion of
patients who discontinued from the study due to lack of efﬁcacy.
Results: Overall, 305 patients were randomized. The mean (SD) age of
patients was 61.6 (8.9) years and 66.6% were female. Both DSPCC 35 mg
TID (86/96, 89.6% [P ¼ 0.007]) and BID (86/102, 84.3% [P ¼ 0.0148])
resulted in signiﬁcantly more patients achieving 10-mm reductions in
the WOMAC pain subscale score from baseline compared with placebo
(67/96, 69.8%) at week 12. Similar effects were noted at week 2 (DSPCC
35 mg TID: 73/94, 77.7% [P ¼ 0.0130]; DSPCC 35 mg BID: 78/100, 78.0%
[P ¼ 0.0098]; placebo: 56/92, 60.9%) and week 6 (DSPCC 35 mg TID: 76/
86, 88.4% [P ¼ 0.0031]; DSPCC 35 mg BID: 76/91, 83.5% [P ¼ 0.0338];
placebo: 61/87, 70.1%). The DSPCC 35 mg TID and BID groups experi-
enced greater reductions in pain intensity compared with placebo.
More than two-thirds of patients in the DSPCC 35 mg TID and BIDgroups achieved a reduction of30% in theWOMAC pain subscale score
from baseline and amajority of patients achieved a reduction of50% at
week 12 based on continuous responder analysis (Table). No patients in
the DSPCC 35 mg TID group and 2 patients (1.9%) in the DSPCC 35 mg
BID group withdrew from the study due to lack of efﬁcacy compared
with 6 patients (5.8%) in the placebo group.Conclusions: Treatment with DSPCC 35 mg TID and BID resulted in
clinically meaningful improvements in pain in this study in patients
with OA of the hip or knee.
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INTRA-ARTICULAR INFILTRATION THERAPY FOR PATIENTS WITH
GLENOHUMERAL OSTEOARTHRITIS. A SYSTEMATIC REVIEW OF THE
LITERATURE.
S. Colen y, P. Geervliet z, D. Haverkamp x, M. van den Bekerom k. yUniv.
Hosp. Leuven, Leuven, Belgium; zGemini Hosp., Dept. of Orthopaedic
Surgery, Den Helder, Netherlands; x Slotervaart Hosp., Dept. of
Orthopaedic Surgery, Amsterdam, Netherlands; kOnze Lieve Vrouwe
Gasthuis, Dept. of Orthopaedic Surgery, Amsterdam, Netherlands
Purpose: Conservative treatments are especially in patients with GH-
OA important, since shoulder arthroplasty has its limitations. In this
systematic review we will evaluate the current evidence regarding the
efﬁcacy of intra-articular inﬁltration treatment options in patients with
glenohumeral osteoarthritis (GH-OA).
Methods: The following databases are searched: Pubmed/Medline,
Cochrane Clinical Trial Register, Embase and the WHO clinical trial
register. All intra-articular injection products used for the treatment of
shoulder OA in humans are included.
Results: A total of 8 studies could be included in this review. Hyaluronic
acid (HA) showed effect sizes of 2.07, 2.02 and 2.11 at 6,12 and 26weeks
follow-up, respectively. Placebo (1.60 , 1.82 and 1.68) also showed stable
effect sizes at the same time points. The efﬁcacy of corticosteroids (CS)
decreased rapidly at follow-up (1.08, 0.43 and 0.19). Although statistical
signiﬁcant, the maximum difference in effect sizes between HA and
placebo was only 0.43 with absolute values between 2.0 and 6.4 on a
100-point VAS for pain.
Conclusion: Intra-articular treatment with HA has a good efﬁcacy at
follow-up compared to baseline. However, the difference in efﬁcacy
between HA and placebo never reaches the minimal clinically impor-
tant difference at any of the follow-up points. We are not able to give
clear recommendations for the use of intra-articular CS injections in
patients with GH-OA. In future research we recommend to focus on
sufﬁciently powered randomized trials to compare the efﬁcacies of HA,
CS, placebo and other intra-articular treatment options in patients with
GH-OA.
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IMPROVEMENT IN CARTILAGE FOLLOWING INTRA-ARTICULAR
INJECTION OF TG-C, A CELL MEDIATED GENE THERAPY FOR
OSTEOARTHRITIS
B. Lee y, S. Totterman z, D. Gale z, A. Schreyer z, J. Cho y, T. Kim y,
Y. Park y, E. Jeong y. yKolon Life Sci., Inc., Gwacheon-si, Republic of Korea;
zQmetrics Tech., Rochester, NY, United States
Purpose: A randomized single-blind phase IIa trial was conducted in 28
patients with knee OA to determine both safety and efﬁcacy of TG-C.
TG-C is a cell mediated gene therapy that contains non-transduced
(hChonJ) and transduced (hChonJb#7) human allogeneic chondrocytes.
hChonJb#7 cells were transduced with TGF-b1 gene using retroviral
vector, while hChonJ cells were not modiﬁed. The hChonJb#7 cells were
